High predictive efficacy of integrase strand transfer inhibitors in perinatally HIV-1-infected African children in therapeutic failure of first- and second-line antiretroviral drug regimens recommended by the WHO.
PMID: 30891603
2019
The Journal of antimicrobial chemotherapy
Discussion: However, polymorphism at position 140, similar to that observed in our study (G140K/R), has been described as leading to a higher genetic barrier for non-B subtypes to acquire the usual accessory INSTI-selected DRMs G140A/C/S at this position.
Discussion: Indeed, at position 140, the usual INSTI-selected accessory mutations are G140A/C/S, which are associated with a 3- to 5-fold reduction in susceptibility to elvitegravir when they occur alone.
Predicted antiviral activity of tenofovir versus abacavir in combination with a cytosine analogue and the integrase inhibitor dolutegravir in HIV-1-infected South African patients initiating or failing first-line ART.
PMID: 30380053
2019
The Journal of antimicrobial chemotherapy
Discussion: We did observe Q148R, which is associated with high-level dolutegravir resistance when accompanied by the G140S/A mutations.
Prevalence and determinants of resistance mutations in HIV-1-infected patients exposed to integrase inhibitors in a large Italian cohort.
Abstract: Overall, the Q148H/K/R plus G140A/C/S and/or E138A/K/T pattern, defining an intermediate level of resistance to DTG, was detected in 70 (15%) cases.
Abstract: The most frequent INSTI resistance mutation was N155H, followed by Q148H/K/R, G140A/C/S, E138A/K/T and Y143C/H/R.
Development of the R263K Mutation to Dolutegravir in an HIV-1 Subtype D Virus Harboring 3 Class-Drug Resistance.
PMID: 30648124
2019
Open forum infectious diseases
Introduction: DTG appears to have a high genetic barrier to resistance, unlike the other drugs within the INSTI class, raltegravir and elvitegravir, which select for major resistance mutations such as N155H, Y143H/R/C, G140A/S, and Q148H/R/K.
Comparison of the Antiviral Activity of Bictegravir against HIV-1 and HIV-2 Isolates and Integrase Inhibitor-Resistant HIV-2 Mutants.
PMID: 30803972
2019
Antimicrobial agents and chemotherapy
Abstract: HIV-2 integrase mutants G140S/Q148R and G140S/Q148H were 34- and 110-fold resistant to bictegravir, respectively; other resistance-associated mutations conferred <=5-fold changes in bictegravir susceptibility.
Consensus Integrase of a New HIV-1 Genetic Variant CRF63_02A1.
Conclusion: The results obtained allowed us to suggest that the resistance of the HIV-1 genetic variant CRF63_02A1 to raltegravir may develop primarily due to the emergence and fixation of Q148K/G140S mutations as it was described for other HIV-1 subtypes.
Table: G140S
Figure: Electrophoretic analysis of the strand transfer reaction products for IN_CRF (lane 2) and its mutants G118R/ E138K (lane 3) and Q148K/G140S (lane 4) (reaction time 300 min).
Figure: Lane 1 - IN_CRF; lane 2 - IN_A; lane 3 - IN_
Resistance to HIV integrase strand transfer inhibitors in Argentina: first interim survey.
PMID: 31037930
2019
Revista espanola de quimioterapia
Abstract: Predominant major mutations were N155H (35.1%), Q148H/R (15.8%) and G140A/S (14%).
Result: Predominant major integrase resistance mutations were N155H (35.1%), Q148H/R (15.8%) and G140A/S (14%).
Table: G140A/S
Raltegravir-Induced Adaptations of the HIV-1 Integrase: Analysis of Structure, Variability, and Mutation Co-occurrence.
Result: The major cluster (A), contains two mutations in the main resistance-related positions (Q148H and N155H), as well as the major resistance mutation G140S.
Result: The resistance-related mutations found in the network were L74M, L74I, T97A, E138K, G140S, Y143R, Q148H, Q148R, N155H, E157Q, G163R, M50I, and S119R.
Result: This observation highlights the fact that T97A does not play a rol
Switching to bictegravir/emtricitabine/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V/I.
PMID: 31430369
2019
The Journal of antimicrobial chemotherapy
Discussion: The impact of G140R in HIV is not known although other non-polymorphic mutations at position 140 including G140S/A/C are associated with 10-100-fold reduced susceptibility of HIV to RAL, EVG, and DTG.
HIV mutation literature information.
PMID: 
2019
The Journal of antimicrobial chemotherapy
Browser Board
Co-occurred Entities
Filtrator
ViMRT